Apyx Medical Corporation (NASDAQ:APYX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Apyx Medical Corporation (NASDAQ:APYX) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $6.50.

A number of research analysts have recently commented on APYX shares. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Friday, March 27th. Craig Hallum increased their target price on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Roth Mkm initiated coverage on Apyx Medical in a research note on Monday, December 15th. They set a “buy” rating and a $6.00 price target on the stock. Finally, BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Wednesday, March 11th.

Hedge Funds Weigh In On Apyx Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new position in shares of Apyx Medical during the third quarter valued at $28,000. Fisher Asset Management LLC bought a new stake in shares of Apyx Medical in the second quarter worth $34,000. Caprock Group LLC acquired a new stake in Apyx Medical in the third quarter valued at $40,000. Hudson Bay Capital Management LP bought a new position in Apyx Medical during the 4th quarter worth $73,000. Finally, Osaic Holdings Inc. bought a new position in Apyx Medical during the 2nd quarter worth $50,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Stock Performance

Shares of Apyx Medical stock opened at $3.68 on Friday. The firm’s 50 day moving average is $3.73 and its 200 day moving average is $3.51. The firm has a market capitalization of $153.93 million, a PE ratio of -13.63 and a beta of 1.54. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $4.50. The company has a current ratio of 5.00, a quick ratio of 4.26 and a debt-to-equity ratio of 2.35.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $19.12 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. Equities research analysts forecast that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.